| NCT ID | NCT03023202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wisconsin, Madison |
| Condition | Hematologic Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2016-03-30 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2016-03-30 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Eligibility Criteria
Inclusion Criteria: * Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document Exclusion Criteria: * Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Contact & Investigator
Dustin Deming, MD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT03023202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03023202 currently recruiting?
Yes, NCT03023202 is actively recruiting participants. Contact the research team at clinicaltrials@cancer.wisc.edu for enrollment information.
Where is the NCT03023202 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT03023202 clinical trial?
NCT03023202 is sponsored by University of Wisconsin, Madison. The principal investigator is Dustin Deming, MD at University of Wisconsin, Madison. The trial plans to enroll 10,000 participants.